Back to Studies
IMPAACT 2050
Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States
Primary Protocol Team Members
Summary
IMPAACT 2050 is a Phase IV study designed to characterize the pharmacokinetics of long-acting injectable cabotegravir (CAB) and rilpivirine (RPV) used in a clinical care setting to treat women living with HIV-1 during pregnancy and postpartum. Women will be followed during pregnancy and then together with their infants through six weeks postpartum.
Site selection was completed in August 2025 and was opened to US-based IMPAACT sites only. Only US sites were invited to participate due to the current market availability of long-acting CAB and RPV.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...